176 related articles for article (PubMed ID: 26915086)
21. Predicted alpha-helix/beta-sheet secondary structures for the zinc-binding motifs of human papillomavirus E7 and E6 proteins by consensus prediction averaging and spectroscopic studies of E7.
Ullman CG; Haris PI; Galloway DA; Emery VC; Perkins SJ
Biochem J; 1996 Oct; 319 ( Pt 1)(Pt 1):229-39. PubMed ID: 8870673
[TBL] [Abstract][Full Text] [Related]
22. Association of E6AP (UBE3A) with human papillomavirus type 11 E6 protein.
Brimer N; Lyons C; Vande Pol SB
Virology; 2007 Feb; 358(2):303-10. PubMed ID: 17023019
[TBL] [Abstract][Full Text] [Related]
23. Computational Analysis of Domains Vulnerable to HPV-16 E6 Oncoprotein and Corresponding Hot Spot Residues.
Malik RM; Fazal S; Kamal MA
Protein Pept Lett; 2021; 28(4):414-425. PubMed ID: 32703126
[TBL] [Abstract][Full Text] [Related]
24. Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus.
Liu Y; Liu Z; Androphy E; Chen J; Baleja JD
Biochemistry; 2004 Jun; 43(23):7421-31. PubMed ID: 15182185
[TBL] [Abstract][Full Text] [Related]
25. Differential localization of HPV16 E6 splice products with E6-associated protein.
Vaeteewoottacharn K; Chamutpong S; Ponglikitmongkol M; Angeletti PC
Virol J; 2005 Jun; 2():50. PubMed ID: 15960845
[TBL] [Abstract][Full Text] [Related]
26. Kinetic analysis of the interactions of human papillomavirus E6 oncoproteins with the ubiquitin ligase E6AP using surface plasmon resonance.
Zanier K; Charbonnier S; Baltzinger M; Nominé Y; Altschuh D; Travé G
J Mol Biol; 2005 Jun; 349(2):401-12. PubMed ID: 15890204
[TBL] [Abstract][Full Text] [Related]
27. Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins.
Baleja JD; Cherry JJ; Liu Z; Gao H; Nicklaus MC; Voigt JH; Chen JJ; Androphy EJ
Antiviral Res; 2006 Oct; 72(1):49-59. PubMed ID: 16690141
[TBL] [Abstract][Full Text] [Related]
28. Involvement of a cellular ubiquitin-protein ligase E6AP in the ubiquitin-mediated degradation of extensive substrates of high-risk human papillomavirus E6.
Matsumoto Y; Nakagawa S; Yano T; Takizawa S; Nagasaka K; Nakagawa K; Minaguchi T; Wada O; Ooishi H; Matsumoto K; Yasugi T; Kanda T; Huibregtse JM; Taketani Y
J Med Virol; 2006 Apr; 78(4):501-7. PubMed ID: 16482544
[TBL] [Abstract][Full Text] [Related]
29. Elucidating Molecular Interactions of Ten Natural Compounds Targeting E6 HPV High Risk Oncoproteins Using Microsecond Molecular Dynamics Simulations.
Meza-Menchaca T; Lizano-Soberón M; Trigos A; Zepeda RC; Medina ME; Galindo-Murillo R
Med Chem; 2021; 17(6):587-600. PubMed ID: 31995016
[TBL] [Abstract][Full Text] [Related]
30. A mutant of human papillomavirus type 16 E6 deficient in binding alpha-helix partners displays reduced oncogenic potential in vivo.
Nguyen M; Song S; Liem A; Androphy E; Liu Y; Lambert PF
J Virol; 2002 Dec; 76(24):13039-48. PubMed ID: 12438630
[TBL] [Abstract][Full Text] [Related]
31. Structure and function of the papillomavirus E6 protein and its interacting proteins.
Liu Y; Baleja JD
Front Biosci; 2008 Jan; 13():121-34. PubMed ID: 17981532
[TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus E6-induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase.
Gao Q; Kumar A; Singh L; Huibregtse JM; Beaudenon S; Srinivasan S; Wazer DE; Band H; Band V
Cancer Res; 2002 Jun; 62(11):3315-21. PubMed ID: 12036950
[TBL] [Abstract][Full Text] [Related]
33. Deciphering the mechanisms of HPV E6 mutations in the destabilization of E6/E6AP/p53 complex.
Li L; Dong X; Tang Y; Lao Z; Li X; Lei J; Wei G
Biophys J; 2022 May; 121(9):1704-1714. PubMed ID: 35364103
[TBL] [Abstract][Full Text] [Related]
34. Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein.
Beerheide W; Bernard HU; Tan YJ; Ganesan A; Rice WG; Ting AE
J Natl Cancer Inst; 1999 Jul; 91(14):1211-20. PubMed ID: 10413422
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of different glutathione S-transferase-tagged protein captures for screening E6/E6AP interaction inhibitors using AlphaScreen.
Sehr P; Pawlita M; Lewis J
J Biomol Screen; 2007 Jun; 12(4):560-7. PubMed ID: 17478484
[TBL] [Abstract][Full Text] [Related]
36. Flavonol and imidazole derivatives block HPV16 E6 activities and reactivate apoptotic pathways in HPV⁺ cells.
Yuan CH; Filippova M; Krstenansky JL; Duerksen-Hughes PJ
Cell Death Dis; 2016 Jan; 7(1):2060. PubMed ID: 26794656
[TBL] [Abstract][Full Text] [Related]
37. 1H and 15N resonance assignment, secondary structure and dynamic behaviour of the C-terminal domain of human papillomavirus oncoprotein E6.
Nominé Y; Charbonnier S; Miguet L; Potier N; Van Dorsselaer A; Atkinson RA; Travé G; Kieffer B
J Biomol NMR; 2005 Feb; 31(2):129-41. PubMed ID: 15772752
[TBL] [Abstract][Full Text] [Related]
38. Identification of E6AP-independent degradation targets of HPV E6.
Vats A; Thatte J; Banks L
J Gen Virol; 2019 Dec; 100(12):1674-1679. PubMed ID: 31609195
[TBL] [Abstract][Full Text] [Related]
39. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300.
Zimmermann H; Degenkolbe R; Bernard HU; O'Connor MJ
J Virol; 1999 Aug; 73(8):6209-19. PubMed ID: 10400710
[TBL] [Abstract][Full Text] [Related]
40. Human papillomavirus type 16 E6 protein interacts with cystic fibrosis transmembrane regulator-associated ligand and promotes E6-associated protein-mediated ubiquitination and proteasomal degradation.
Jeong KW; Kim HZ; Kim S; Kim YS; Choe J
Oncogene; 2007 Jan; 26(4):487-99. PubMed ID: 16878151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
